Use of 3D transabdominal ultrasound imaging for treatment planning in cervical cancer brachytherapy: Comparison to magnetic resonance and computed tomography.


Journal Article

PURPOSE: To evaluate if the addition of 3D transabdominal ultrasound (3DTAUS) imaging to computed tomography (CT) can improve treatment planning in 3D adaptive brachytherapy when compared with CT-based planning alone, resulting in treatment plans closer to the ones obtained using magnetic resonance imaging (MRI)-based planning. METHODS AND MATERIALS: Five patients with cervical cancer undergoing brachytherapy underwent three imaging modalities: MRI, CT, and CT-3DTAUS. Volumes were delineated by a radiation oncologist and treatment plans were optimized on each imaging modality. To compare treatment plans, the dwell times optimized on MRI were transferred on CT and CT-3DTAUS images and dose parameters were reported on volumes of the receiving imaging modality. The plans optimized on CT and CT-3DTAUS were also copied and evaluated on MRI images. RESULTS: Treatment plans optimized and evaluated on the same imaging modalities were clinically acceptable but statistically different (p < 0.05) from one another. MR-based plans had the highest target coverage (98%) and CT-based plans the lowest (93%). For all treatment plans evaluated on MRI, the target coverage was equivalent. However, a decrease in target coverage (V100) was observed when MR-based plans were applied on CT-3DTAUS (6%) and CT (13%) with p < 0.05. An increase in the rectum/sigmoid dose (D2cc) was observed with both CT-3DTAUS-based (0.6 Gy) and CT-based planning (1 Gy) when compared with MR-based plans, whereas bladder dose stayed similar. CONCLUSIONS: When compared with CT-based planning, the addition of 3DTAUS to CT results in treatment plans closer to MR-based planning. Its use reduces the high-risk clinical target volume overestimation typically observed on CT, improving coverage of the target volume while reducing dose to the organs at risk.

Full Text

Duke Authors

Cited Authors

  • St-Amant, P; Foster, W; Froment, M-A; Aubin, S; Lavallée, M-C; Beaulieu, L

Published Date

  • July 2017

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 847 - 854

PubMed ID

  • 28455092

Pubmed Central ID

  • 28455092

Electronic International Standard Serial Number (EISSN)

  • 1873-1449

Digital Object Identifier (DOI)

  • 10.1016/j.brachy.2017.03.006


  • eng

Conference Location

  • United States